+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Fragile X Syndrome Drug"

Fragile X Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Fragile X Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 80 Pages
  • Global
From
From
Fragile X Syndrome (FXS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Fragile X Syndrome (FXS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
From
From
Fragile X Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Fragile X Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 194 Pages
  • Global
From
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Fragile X Syndrome (FXS) is a genetic disorder that is the most common inherited cause of intellectual disability and autism. It is caused by a mutation in the FMR1 gene, which leads to an absence of the FMRP protein. As a result, individuals with FXS experience a range of cognitive, behavioral, and physical symptoms. The Fragile X Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs that are used to treat the symptoms of FXS, such as cognitive impairment, anxiety, and hyperactivity. These drugs are typically prescribed by neurologists and psychiatrists, and may include antipsychotics, antidepressants, and stimulants. The Fragile X Syndrome Drug market is a growing field, as more research is conducted into the disorder and its treatment. Companies in this market include Shire, Novartis, and Ovid Therapeutics. Show Less Read more